BPA
ADMA icon

Beacon Pointe Advisors’s ADMA Biologics ADMA Stock Holding History

Beacon Pointe Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,653
Closed -$70.3K – 1269
2024
Q1 		$70.3K Buy
+10,653
New +$58.2K ﹤0.01% 1320
2023
Q2 		– Sell
-14,915
Closed -$49.4K – 1077
2023
Q1 		$49.4K Sell
14,915
-45
-0.3% -$156 ﹤0.01% 1118
2022
Q4 		$58K Hold
14,960
– – ﹤0.01% 1038
2022
Q3 		$36K Buy
+14,960
New +$35.9K ﹤0.01% 984
2022
Q2 		– Sell
-23,490
Closed -$43K – 1039
2022
Q1 		$43K Sell
23,490
-4,460
-16% -$6.96K ﹤0.01% 1176
2021
Q4 		$39K Buy
+27,950
New +$36.7K ﹤0.01% 916

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Beacon Pointe Advisors's ADMA Position: Q2 2024 in Review

Beacon Pointe Advisors sold out of ADMA Biologics (ADMA) in Q2 2024, closing a stake of 10,653 shares — an estimated $70.3K sold.

Beacon Pointe Advisors first reported a position in ADMA in Q4 2021 and held it in 6 quarters. The position peaked at $70.3K in Q1 2024. 252 funds tracked by Wall St. Rank hold ADMA as of Q2 2024.

  • Beacon Pointe Advisors reported no remaining ADMA Biologics position as of Q2 2024 after selling out during the quarter.
  • Beacon Pointe Advisors sold 10,653 ADMA Biologics shares in Q2 2024, an estimated $70.3K.
  • Beacon Pointe Advisors first reported a position in ADMA Biologics in Q4 2021 and held it in 6 quarters.
  • Beacon Pointe Advisors's ADMA Biologics position peaked at $70.3K in Q1 2024.
  • 252 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2024.

Based on Beacon Pointe Advisors's 13F filing for Q2 2024, filed 12 Aug 2024.